Wall Street Bulls Look Optimistic About CRISPR Therapeutics (CRSP): Should You Buy?Zacks Investment Research • 10/05/26
CRISPR Therapeutics to Present Clinical Data on Zugocabtagene Geleucel (Zugo-cel) in Autoimmune Disease at the American College of Rheumatology (ACR) Convergence 2026GlobeNewsWire • 10/02/26
CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should KnowZacks Investment Research • 09/29/26
CRISPR Therapeutics Has 2 Key Catalysts Coming by the End of 2026. Is the Market Underestimating Them?The Motley Fool • 09/29/26
CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: Here's WhyZacks Investment Research • 09/25/26
Crispr Therapeutics: Why AI Giant Anthropic's Discovery Has Rocked Gene EditingSeeking Alpha • 09/24/26
CRISPR Therapeutics vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?The Motley Fool • 09/24/26
CRISPR Therapeutics Traded Sideways and Down for 12 Months: One Wall Street Pro Expects 85% Gains Soon24/7 Wall Street • 09/23/26
Where Will CRISPR Therapeutics Be in 10 Years if Gene Editing Fulfills Its Promise?The Motley Fool • 09/18/26
Wall Street Analysts Think CRISPR Therapeutics (CRSP) Is a Good Investment: Is It?Zacks Investment Research • 09/17/26
CRISPR Therapeutics AG (CRSP) Sees a More Significant Dip Than Broader Market: Some Facts to KnowZacks Investment Research • 09/15/26
CRISPR Therapeutics AG (CRSP) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeeking Alpha • 09/14/26
AbbVie vs. CRISPR Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?The Motley Fool • 09/14/26
Amgen vs. CRISPR Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?The Motley Fool • 09/11/26
Axsome Therapeutics vs. CRISPR Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?The Motley Fool • 09/11/26
CRISPR Therapeutics to Present at the Morgan Stanley 24th Annual Global Healthcare ConferenceGlobeNewsWire • 09/08/26
CRISPR Therapeutics: CASGEVY Validates The Platform, Strengthening The Acquisition CaseSeeking Alpha • 09/05/26
2 Reasons CRISPR Therapeutics Stock Could Soar in the Final 4 Months of 2026The Motley Fool • 09/02/26